These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11840155)

  • 1. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.
    Gianni AM; Cortelazzo S; Magni M; Martelli M;
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S10-3. PubMed ID: 11840155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].
    Takasaki H; Hashimoto C; Takemura S; Motomura S; Ishigatsubo Y
    Rinsho Ketsueki; 2010 Jan; 51(1):57-62. PubMed ID: 20134141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
    Pettengell R
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S1-4. PubMed ID: 11840153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo purging and relapse prevention following ASCT.
    Gisselbrecht C
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S5-9. PubMed ID: 11840154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.
    Thieblemont C; Antal D; Lacotte-Thierry L; Delwail V; Espinouse D; Michallet AS; Traulle C; Bouafia-Sauvy F; Giraud C; Salles G; Guilhot F; Coiffier B
    Cancer; 2005 Oct; 104(7):1434-41. PubMed ID: 16104036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
    Berinstein NL; Buckstein R; Imrie K; Spaner D; Mangel J; Tompkins K; Pennell N; Reis M; Pavlin P; Lima A; Couvadia A; Robinson J; Richardson P
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S14-7. PubMed ID: 11840156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
    Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
    Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
    Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
    Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
    Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
    Gianni AM; Magni M; Martelli M; Di Nicola M; Carlo-Stella C; Pilotti S; Rambaldi A; Cortelazzo S; Patti C; Parvis G; Benedetti F; Capria S; Corradini P; Tarella C; Barbui T
    Blood; 2003 Jul; 102(2):749-55. PubMed ID: 12663455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
    Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas.
    Tóthová E; Kafková A; Guman T; Stecová N; Fricová M
    Neoplasma; 2003; 50(1):22-5. PubMed ID: 12687274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
    Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
    J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.